Yashwant Chaudhri, MD
Psychiatry · Santee, CANPI 1043258429
Payments from drug & device makers
Across 588 payments — averaging $2644.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$861K
- Janssen Research & Development, LLC$264K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$193K
- Sumitomo Pharma America, Inc.$179K
- Shire North American Group Inc$16K
- Pfizer$11K
- plus $31K from 22 others
Across 30 payments — averaging $114.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- Teva Pharmaceuticals USA, Inc.$760
What the payments were for
- Speaking & faculty fees$3,11322%
- Travel & lodging$1,1918%
- Food & beverage$8,37159%
- Education$771%
- Other$1,40010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 141 | $861,345 |
| Janssen Research & Development, LLC | 33 | $264,421 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 8 | $192,585 |
| Sumitomo Pharma America, Inc. | 99 | $179,149 |
| Shire North American Group Inc | 7 | $15,566 |
| Pfizer | 27 | $10,560 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $7,390 |
| Livanova USA, Inc. | 9 | $6,571 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $6,339 |
| Brainsway USA Inc | 1 | $3,113 |
| Neuronetics, Inc. | 30 | $2,185 |
| Neurocrine Biosciences, Inc. | 54 | $1,436 |
| Johnson & Johnson | 38 | $1,194 |
| Otsuka America Pharmaceutical, Inc. | 28 | $780 |
| Alkermes, Inc. | 25 | $733 |
| AbbVie(2 entities) | 20 | $399 |
| E.r. Squibb & Sons, L.L.C. | 13 | $365 |
| Sunovion Pharmaceuticals Inc. | 7 | $211 |
| Axsome Therapeutics, Inc. | 2 | $143 |
| Vanda Pharmaceuticals Inc. | 4 | $126 |
| Amgen | 1 | $122 |
| Neurelis, Inc. | 1 | $118 |
| Sanofi | 1 | $76 |
| Indivior Inc. | 2 | $47 |
| Tempus AI, Inc | 2 | $42 |
| Tris Pharma Inc | 1 | $24 |
| Lundbeck LLC | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Brainsway Deep TMS$3,113
- NEUROSTAR TMS THERAPY SYSTEM$1,400
- VNS Therapy$1,328
- ARISTADA$500
- LYBALVI$475
- INGREZZA$390
- INVEGA SUSTENNA$389
- UZEDY$236
- COBENFY$132
- ARISTADA INITIO$125
- UPLIZNA$122
- Auvelity$122
- ABILIFY MAINTENA$121
- ABILIFY ASIMTUFII$121
- REXULTI$120
- VALTOCO$118
- SPRAVATO$113
- AUSTEDO$112
How this compares
$1,555,076 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 187 | $519,063 |
| IngrezzaValbenazine Tosylate | 14 | $105,241 |
| ClozarilClozapine | 39 | $45,795 |
| Chlorpromazine Hcl | 192 | $36,828 |
| Aripiprazole | 138 | $14,703 |
| Quetiapine Fumarate | 854 | $12,610 |
| Clozapine | 130 | $11,601 |
| Divalproex Sodium | 172 | $8,451 |
| Divalproex Sodium ErDivalproex Sodium | 165 | $6,673 |
| Trazodone Hcl | 513 | $6,417 |
| Paliperidone ErPaliperidone | 35 | $5,575 |
| Haloperidol | 143 | $5,268 |
| Lurasidone Hcl | 48 | $5,033 |
| Risperidone | 404 | $4,865 |
| Perphenazine | 36 | $3,406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,194 | $519,063187 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,436 | $105,24114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Santee
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.